

**Amendments to the Specification:**

Page 1, before line 1, insert:

**Cross Reference to Related Application**

This application is a 35 USC § 371 National Phase Entry Application from PCT/EP2004/008053, filed July 19, 2004, and designating the United States.

The additions have been indicated by underlining (underlining).

**Please replace the first paragraph on page 21 with the following amended paragraph:**

Figure 3 shows the sequence of the newly identified 7a5/Prognostin-cDNA [SEQ ID NO: 1] as well as the putative protein sequence [SEQ ID NO: 2]; characteristic interaction domains are indicated,

**Please replace the paragraph which spans page 27 fourth paragraph through page 28 first paragraph with the following amended paragraph:**

The primary polyclonal rabbit-anti-human 7a5 antibody was raised against a 7a5-derived polypeptide (AA 812-826, localised near the C-terminus: (KLH)-SALDRMKNPVTKHWR [SEQ ID NO: 8], Eurogentec, Seraing, Belgium) and was purified by means of affinity chromatography with the peptide antigen coupled to CNBr-sepharose (BioGenes, Berlin, DE) in the following. This antibody was used for immunohistochemistry in a dilution of 1:1000. In order to avoid the non-specific antibody-based Fc-receptor ligation, an Fc-depleted biotinylated affinity-pure F(ab')<sub>2</sub>-fragment antibody with anti-rabbit specificity (dilution 1:40,000, Dianova-Jackson ImmunoResearch, Hamburg, DE) was used. The Streptavidin-HRP was used for 15 minutes at room temperature. The colorimetric detection was performed under the employment of DAB substrate according to the protocol provided by the

manufacturer. The nuclei were counterstained with haematoxylin for 1 minute. The sections were analysed according to topographical aspects of expression.